RLMD

The Week

Capricor Therap fell 11.62% this week to close at $5.93, while the S&P 500 slipped 0.47%. The stock underperformed the benchmark by roughly 11.15 percentage points. The week opened at $6.82 on Monday and touched an intraday high of $6.93 before settling at $6.65. Wednesday brought a sharp move lower, with the stock breaking below $6 and hitting a week low of $5.79. It rebounded to $6.13 on Thursday, then pulled back to $5.93 on Friday. There was no major catalyst, and volume ran about 27% below its recent daily median.

Analyst Ratings

Among the 10 brokers covering the stock, 3 rate it buy, 1 rate it overweight, and 6 rate it hold; none carry a sell or underweight rating. The consensus rating is buy, with a consensus target of $27 — about 355% above the current price. Individual targets range widely from $7 to $54. Within the biotechnology industry, the stock ranks 158th out of 511 names, placing it in the lower middle of the group.

The Week Ahead

The macro calendar is busy next week. Tuesday brings durable goods orders, FHFA house prices, the Case Shiller 20-city index, new home sales, and consumer confidence. There are no company-specific events on the near-term calendar. Capricor’s next earnings release is scheduled for 11 November after market close, covering fiscal Q3 2026; consensus estimates point to a loss of $0.42 per share on revenue of $10.4m.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.